Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Current Liabilities
All obligations due within one year.
Citius Oncology, Inc.NASDAQ: CTOR
Total Current Liabilities · Q2 FY2026 · quarter ended Mar 2026
Total current liabilities rises 18.2% from a year ago
Total current liabilities stood at $58.81M at the end of Q2 FY2026, up 18.2% from a year earlier and up 31.5% from the prior quarter. Over 3 fiscal years it compounded at +103.8% a year.
Context
- Total current liabilities amounted to 58.4% of total assets at the end of Q2 FY2026, up 4.0 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +18.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 49.49M USD
- Year-over-year change
- +51.3%
- 3-year CAGR
- +103.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 49.49M | +51.3% |
| FY2024 | 2024-09-30 | 32.7M | +55.4% |
| FY2023 | 2023-09-30 | 21.05M | +260.0% |
| FY2022 | 2022-09-30 | 5.85M | — |
Total Current Liabilities vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total current liabilities of $58.81M is the 2nd highest of the 10 companies compared; the peer median is $19.34M.
- Its year-over-year change of +18.2% is the 4th highest of 10, against a peer median of -3.9%.
- Total current liabilities amounts to 58.4% of total assets for CTOR, versus a peer median of 26.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $501.75M | +82.0% | +120.9% | 170.9% | |
CTORCitius Oncology, Inc. | Mar 2026 | $58.81M | +18.2% | +103.8% | 58.4% |
| Mar 2026 | $48.14M | +18.3% | -12.8% | 55.5% | |
| Mar 2026 | $30.69M | +9.0% | -31.9% | 10.8% | |
| Mar 2026 | $23.65M | +161.8% | +86.9% | 35.2% | |
| Mar 2026 | $19.34M | -38.2% | -39.1% | 16.4% | |
| Mar 2026 | $17.8M | -34.5% | +52.6% | 26.9% | |
| Mar 2026 | $16.08M | -3.9% | +24.3% | 3.2% | |
| Mar 2026 | $5.49M | -81.2% | -25.7% | 9.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $4.72M | -48.4% | +9.5% | 53.0% |
| Peer median (excluding CTOR) | $19.34M | -3.9% | +9.5% | 26.9% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.